Results 21 to 30 of about 2,591,141 (428)

Coaxing the LDL Receptor Family into the Fold [PDF]

Cell, 2003
Low-density-lipoprotein (LDL) receptor family members control diverse developmental and physiological pathways. In this issue of Cell, both Culi and Mann and Hsieh et al. report on Boca/MESD, a highly conserved chaperone required for transport of LDLR family proteins to the cell surface.
Joachim Herz, Peter Marschang
openaire   +3 more sources

Detection of large deletions in the LDL receptor gene with quantitative PCR methods [PDF]

, 2005
BACKGROUND: Familial Hypercholesterolemia (FH) is a common genetic disease and at the molecular level most often due to mutations in the LDL receptor gene.
Anette Stenderup, CT Wittwer, D Damgaard, Dorte Damgaard, F Joncourt, Gitte G Nielsen, H Nissen, HH Hobbs, HK Jensen, I Laurendeau, J Wang, J Wilhelm, JJ Gille, JL Goldstein, JP Schouten, K De Preter, K Wilke, KE Heath, L Villeger, Lillian G Jensen, Mogens L Larsen, NS Rudiger, OK Rodningen, Ole Faergeman, Peter H Nissen, SH Kim, SW Fouchier, WM Freeman, XM Sun   +28 more
core   +2 more sources

Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein

Nature Communications, 2018
Vesicular stomatitis virus (VSV) is an oncolytic rhabdovirus and its glycoprotein G is widely used to pseudotype other viruses for gene therapy. Low-density lipoprotein receptor (LDL-R) serves as a major entry receptor for VSV. Here we report two crystal
Jovan Nikolic, Laura Belot, H. Raux, Pierre Legrand, Y. Gaudin, Aurélie A. Albertini   +5 more
semanticscholar   +1 more source

Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia [PDF]

, 2017
Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsive
Averna M. R., Bloedon L. T., Blom D. J., Cuchel M., Foulds P., Gaudet D., Hegele R. A., Larrey D., Meagher E. A., Rader D. J., Shah P. K., Sirtori C. R., Stefanutti C., Toit Theron H. D., Vigna G. B.   +14 more
core   +1 more source

Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex

Scientific Reports, 2018
CRISPR/Cas gene studies were conducted in HeLa cells where either PGRMC1, TMEM97 or both proteins were removed via gene editing. A series of radioligand binding studies, confocal microscopy studies, and internalization of radiolabeled or fluorescently ...
A. Riad, C. Zeng, Chi-Chang Weng, Harrison D. Winters, Kuiying Xu, Mehran Makvandi, Tyler A Metz, S. Carlin, R. Mach   +8 more
semanticscholar   +1 more source

Thoroughly analysis of the phase diagram for the Bell-Lavis model: An entropic simulational study [PDF]

, 2020
In this work, we investigate the Bell-Lavis model using entropic simulations for several values of the energy parameters. The $T\times\mu$ phase diagram and the ground state configurations are analyzed thoroughly. Besides, we examine the particle density and specific heat behavior for different values of the chemical potential $\mu$ as functions of ...
arxiv   +1 more source

ELISA measurement of LDL receptors

Journal of Lipid Research, 1990
An enzyme-linked immunosorbent assay was developed for measurement of low density lipoprotein (LDL) receptors. A monospecific polyclonal antibody to LDL receptor purified from rat liver that reacted with rat, mouse, canine, and human LDL receptor was used.
Allen D. Cooper, K May, Jean Chen, Fredric B. Kraemer   +3 more
openaire   +4 more sources

Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-β-D-arabinofuranosylcytosine in Daudi lymphoma cells [PDF]

, 1999
Low density lipoprotein (LDL) receptor-mediated uptake and cytotoxic effects of N4-octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC) were studied in Daudi lymphoma cells.
BA Allison, CF Yen, CF Yen, DH Horber, DH Horber, DH Horber, F Jasanada, F Rinninger, Herbert Schott, I Abe, IE Morrison, J Swanson, JL Goldstein, JL Goldstein, KM Wasan, M MacCoss, PCN Rensen, RA Firestone, RA Schwendener, RL Juliano, S Vitols, SKM Koller-Lucae, SKM Koller-Lucae, TJ van Berkel, V Viallard, W Rubas, WR Vogler, ZF Stephan   +27 more
core   +2 more sources

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role[S]

Journal of Lipid Research, 2016
Lipoprotein (a) [Lp(a)] is independently associated with CVD risk. Evolocumab, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9 (PCSK9), decreases Lp(a). The potential mechanisms were assessed.
F. Raal, R. Giugliano, M. Sabatine, M. Koren, D. Blom, N. Seidah, Narimon Honarpour, Armando Lira, Allen Xue, P. Chiruvolu, Simon Jackson, Mei Di, M. Peach, R. Somaratne, S. Wasserman, R. Scott, E. Stein   +16 more
semanticscholar   +1 more source

High bone density due to a mutation in LDL-receptor-related protein 5.

New England Journal of Medicine, 2002
BACKGROUND Osteoporosis is a major public health problem of largely unknown cause. Loss-of-function mutations in the gene for low-density lipoprotein receptor-related protein 5 (LRP5), which acts in the Wnt signaling pathway, have been shown to cause ...
L. Boyden, J. Mao, J. Belsky, L. Mitzner, Anita Farhi, M. Mitnick, Dianqing Wu, K. Insogna, R. Lifton   +8 more
semanticscholar   +1 more source